2-214809599-C-G

Variant summary

Our verdict is Benign. The variant received -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBA1

The ENST00000613192.2(BARD1):​n.-30G>C variant causes a non coding transcript exon change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.715 in 1,529,042 control chromosomes in the GnomAD database, including 391,704 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★).

Frequency

Genomes: 𝑓 0.74 ( 41389 hom., cov: 35)
Exomes 𝑓: 0.71 ( 350315 hom. )

Consequence

BARD1
ENST00000613192.2 non_coding_transcript_exon

Scores

2

Clinical Significance

Benign criteria provided, multiple submitters, no conflicts B:4

Conservation

PhyloP100: -0.234

Publications

28 publications found
Variant links:
Genes affected
BARD1 (HGNC:952): (BRCA1 associated RING domain 1) This gene encodes a protein which interacts with the N-terminal region of BRCA1. In addition to its ability to bind BRCA1 in vivo and in vitro, it shares homology with the 2 most conserved regions of BRCA1: the N-terminal RING motif and the C-terminal BRCT domain. The RING motif is a cysteine-rich sequence found in a variety of proteins that regulate cell growth, including the products of tumor suppressor genes and dominant protooncogenes. This protein also contains 3 tandem ankyrin repeats. The BARD1/BRCA1 interaction is disrupted by tumorigenic amino acid substitutions in BRCA1, implying that the formation of a stable complex between these proteins may be an essential aspect of BRCA1 tumor suppression. This protein may be the target of oncogenic mutations in breast or ovarian cancer. Multiple alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Sep 2013]
SNHG31 (HGNC:54196): (small nucleolar RNA host gene 31)

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -20 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.85).
BP6
Variant 2-214809599-C-G is Benign according to our data. Variant chr2-214809599-C-G is described in ClinVar as Benign. ClinVar VariationId is 334199.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BA1
GnomAd4 highest subpopulation (EAS) allele frequency at 95% confidence interval = 0.78 is higher than 0.05.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
BARD1NM_000465.4 linkc.-30G>C 5_prime_UTR_variant Exon 1 of 11 ENST00000260947.9 NP_000456.2 Q99728-1A0AVN2

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
BARD1ENST00000260947.9 linkc.-30G>C 5_prime_UTR_variant Exon 1 of 11 1 NM_000465.4 ENSP00000260947.4 Q99728-1

Frequencies

GnomAD3 genomes
AF:
0.737
AC:
111994
AN:
152010
Hom.:
41325
Cov.:
35
show subpopulations
Gnomad AFR
AF:
0.759
Gnomad AMI
AF:
0.685
Gnomad AMR
AF:
0.783
Gnomad ASJ
AF:
0.722
Gnomad EAS
AF:
0.800
Gnomad SAS
AF:
0.667
Gnomad FIN
AF:
0.762
Gnomad MID
AF:
0.715
Gnomad NFE
AF:
0.711
Gnomad OTH
AF:
0.721
GnomAD2 exomes
AF:
0.734
AC:
102538
AN:
139724
AF XY:
0.726
show subpopulations
Gnomad AFR exome
AF:
0.764
Gnomad AMR exome
AF:
0.815
Gnomad ASJ exome
AF:
0.715
Gnomad EAS exome
AF:
0.804
Gnomad FIN exome
AF:
0.782
Gnomad NFE exome
AF:
0.708
Gnomad OTH exome
AF:
0.713
GnomAD4 exome
AF:
0.712
AC:
980672
AN:
1376914
Hom.:
350315
Cov.:
50
AF XY:
0.710
AC XY:
481575
AN XY:
677870
show subpopulations
African (AFR)
AF:
0.761
AC:
23901
AN:
31422
American (AMR)
AF:
0.810
AC:
28957
AN:
35740
Ashkenazi Jewish (ASJ)
AF:
0.711
AC:
17847
AN:
25104
East Asian (EAS)
AF:
0.767
AC:
27245
AN:
35512
South Asian (SAS)
AF:
0.668
AC:
52999
AN:
79396
European-Finnish (FIN)
AF:
0.782
AC:
27517
AN:
35168
Middle Eastern (MID)
AF:
0.687
AC:
3077
AN:
4480
European-Non Finnish (NFE)
AF:
0.707
AC:
758001
AN:
1072780
Other (OTH)
AF:
0.718
AC:
41128
AN:
57312
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.489
Heterozygous variant carriers
0
15428
30856
46285
61713
77141
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
19430
38860
58290
77720
97150
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.737
AC:
112116
AN:
152128
Hom.:
41389
Cov.:
35
AF XY:
0.739
AC XY:
54998
AN XY:
74380
show subpopulations
African (AFR)
AF:
0.759
AC:
31511
AN:
41506
American (AMR)
AF:
0.784
AC:
11992
AN:
15294
Ashkenazi Jewish (ASJ)
AF:
0.722
AC:
2504
AN:
3470
East Asian (EAS)
AF:
0.801
AC:
4129
AN:
5158
South Asian (SAS)
AF:
0.668
AC:
3220
AN:
4820
European-Finnish (FIN)
AF:
0.762
AC:
8083
AN:
10602
Middle Eastern (MID)
AF:
0.718
AC:
211
AN:
294
European-Non Finnish (NFE)
AF:
0.711
AC:
48311
AN:
67960
Other (OTH)
AF:
0.724
AC:
1533
AN:
2116
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.502
Heterozygous variant carriers
0
1576
3153
4729
6306
7882
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
846
1692
2538
3384
4230
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.722
Hom.:
7277
Bravo
AF:
0.741
Asia WGS
AF:
0.740
AC:
2572
AN:
3478

ClinVar

Significance: Benign
Submissions summary: Benign:4
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not provided Benign:2
Mar 03, 2015
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

-
Breakthrough Genomics, Breakthrough Genomics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:not provided

- -

Familial cancer of breast Benign:1
Jan 13, 2018
Illumina Laboratory Services, Illumina
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as benign is not then subjected to further curation. The score for this variant resulted in a classification of benign for this disease. -

Hereditary breast ovarian cancer syndrome Benign:1
Apr 19, 2022
National Health Laboratory Service, Universitas Academic Hospital and University of the Free State
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.85
CADD
Benign
6.0
DANN
Benign
0.40
PhyloP100
-0.23
PromoterAI
0.022
Neutral
RBP_binding_hub_radar
0.0
RBP_regulation_power_radar
1.1
Mutation Taster
=300/0
polymorphism (auto)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs1129804; hg19: chr2-215674323; API